本研究では、個別化薬物治療を目指し、抗がん剤の複雑な薬物動態に関与する単光子放出断層撮像法を用いた高精度多剤耐性予測法の確立を目的とした。その結果、これまで同じ多剤耐性予測をもたらすと報告されていた[99mTc]sestamibiと[99mTc]tetrofosminにおいて、[99mTc]sestamibiはMDR1とMRP1、一方[99mTc]tetrofosminはMDR1とMRP1-3に親和性があり、各々異なる多剤耐性予測法と成り得ることが判明した。また、[131I]adsterolはBCRPのみに親和性があり、更に高精度な予測法となる可能性を見出した。
We developed high an accuracy multidrug resistance prediction method using SPECT imaging for individualized anticancer therapy. Although [99mTc]sestamibi and [99mTc]tetrofosmin has been reported to be the same method, we clarified that [99mTc]sestamibi had affinity to MDR1 and MRP1, whereas [99mTc]tetrofosmin had affinity to MDR1 and MRP1-3. Thus, these SPECT tracers had different method for multidrug resistance prediction in this study. Additionally, [131I]adsterol was possibility to be higher accuracy multidrug resistance prediction method than [99mTc]sestamibi and [99mTc]tetrofosmin because [131I]adsterol had only affinity to BCRP.